HC Wainwright Analysts Boost Earnings Estimates for ATNM

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – HC Wainwright increased their Q2 2026 earnings estimates for shares of Actinium Pharmaceuticals in a research report issued on Tuesday, May 12th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.20) per share for the quarter, up from their prior forecast of ($0.25). The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.29) EPS, FY2026 earnings at ($0.91) EPS and FY2027 earnings at ($0.67) EPS.

Separately, Stephens reiterated an “overweight” rating and set a $5.00 price objective on shares of Actinium Pharmaceuticals in a research report on Tuesday, March 31st. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $4.50.

Actinium Pharmaceuticals Price Performance

ATNM stock opened at $1.29 on Thursday. The company has a 50 day simple moving average of $1.17 and a 200 day simple moving average of $1.28. The stock has a market cap of $40.47 million, a price-to-earnings ratio of -0.93 and a beta of -0.11. Actinium Pharmaceuticals has a 1 year low of $0.95 and a 1 year high of $1.95.

Institutional Investors Weigh In On Actinium Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ATNM. Bank of America Corp DE grew its holdings in Actinium Pharmaceuticals by 76.6% during the 4th quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock worth $99,000 after acquiring an additional 34,176 shares during the last quarter. AQR Capital Management LLC grew its holdings in Actinium Pharmaceuticals by 278.6% during the 1st quarter. AQR Capital Management LLC now owns 63,249 shares of the company’s stock worth $102,000 after acquiring an additional 46,545 shares during the last quarter. Marshall Wace LLP bought a new stake in Actinium Pharmaceuticals during the 2nd quarter worth approximately $137,000. Qube Research & Technologies Ltd bought a new stake in Actinium Pharmaceuticals during the 2nd quarter worth approximately $70,000. Finally, Jane Street Group LLC bought a new stake in Actinium Pharmaceuticals during the 2nd quarter worth approximately $306,000. 27.50% of the stock is owned by institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.